Literature DB >> 29433017

Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies.

Carina Eklund1, Ola Forslund2, Keng-Ling Wallin3, Joakim Dillner4.   

Abstract

BACKGROUND: Accurate and internationally comparable human papillomavirus (HPV) DNA detection and typing services are essential for HPV vaccine research and surveillance.
OBJECTIVES: This study assessed the proficiency of different HPV typing services offered routinely in laboratories worldwide. STUDY
DESIGN: The HPV Laboratory Network (LabNet) has designed international proficiency panels that can be regularly issued. The HPV genotyping proficiency panels of 2013 and 2014 contained 43 and 41 coded samples, respectively, composed of purified plasmids of sixteen HPV types (HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68a and 68b) and 3 extraction controls. Proficient typing was defined as detection in both single and multiple infections of 50 International Units of HPV 16 and HPV 18 and 500 genome equivalents for the other 14 HPV types, with at least 97% specificity.
RESULTS: Ninety-six laboratories submitted 136 datasets in 2013 and 121 laboratories submitted 148 datasets in 2014. Thirty-four different HPV genotyping assays were used, notably Linear Array, HPV Direct Flow-chip, GenoFlow HPV array, Anyplex HPV 28, Inno-LiPa, and PGMY-CHUV assays. A trend towards increased sensitivity and specificity was observed. In 2013, 59 data sets (44%) were 100% proficient compared to 86 data sets (59%) in 2014. This is a definite improvement compared to the first proficiency panel, issued in 2008, when only 19 data sets (26%) were fully proficient.
CONCLUSION: The regularly issued global proficiency program has documented an ongoing worldwide improvement in comparability and reliability of HPV genotyping services.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  International standards; Quality assurance; Vaccinology

Mesh:

Year:  2018        PMID: 29433017     DOI: 10.1016/j.jcv.2018.01.016

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  7 in total

1.  Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.

Authors:  Lan Xu; Anja Oštrbenk Valenčak; Mario Poljak; Marc Arbyn
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

2.  Cross comparison of AmpFire HPV genotyping assay and Roche human papillomavirus (HPV) linear array for HPV genotyping of anal swab samples.

Authors:  Kaleigh A Connors; Stephen Abbott; Kamwing Jair; Jason Daniels; Madison Lintner; David Klein; Avery Wimpleberg; Jeanne A Jordan
Journal:  J Virol Methods       Date:  2021-02-27       Impact factor: 2.623

3.  Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening.

Authors:  Marion Saville; Farhana Sultana; Michael J Malloy; Louiza S Velentzis; Michael Caruana; Ellen L O Ip; Marco H T Keung; Karen Canfell; Julia M L Brotherton; David Hawkes
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

4.  Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study.

Authors:  Richard Muwonge; Partha Basu; Tarik Gheit; Devasena Anantharaman; Yogesh Verma; Neerja Bhatla; Smita Joshi; Pulikottil O Esmy; Usha Rani Reddy Poli; Anand Shah; Eric Zomawia; Surendra S Shastri; Sharmila Pimple; Priya R Prabhu; Sanjay Hingmire; Aruna Chiwate; Catherine Sauvaget; Eric Lucas; Sylla G Malvi; Maqsood Siddiqi; Subha Sankaran; Thiraviam Pillai Rameshwari Ammal Kannan; Rintu Varghese; Uma Divate; Shachi Vashist; Gauravi Mishra; Radhika Jadhav; Massimo Tommasino; M Radhakrishna Pillai; Rengaswamy Sankaranarayanan; Kasturi Jayant
Journal:  PLoS One       Date:  2020-12-29       Impact factor: 3.240

5.  Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.

Authors:  Partha Basu; Sylla G Malvi; Smita Joshi; Neerja Bhatla; Richard Muwonge; Eric Lucas; Yogesh Verma; Pulikkottil O Esmy; Usha Rani Reddy Poli; Anand Shah; Eric Zomawia; Sharmila Pimple; Kasturi Jayant; Sanjay Hingmire; Aruna Chiwate; Uma Divate; Shachi Vashist; Gauravi Mishra; Radhika Jadhav; Maqsood Siddiqi; Subha Sankaran; Priya Ramesh Prabhu; Thiraviam Pillai Rameshwari Ammal Kannan; Rintu Varghese; Surendra S Shastri; Devasena Anantharaman; Tarik Gheit; Massimo Tommasino; Catherine Sauvaget; M Radhakrishna Pillai; Rengaswamy Sankaranarayanan
Journal:  Lancet Oncol       Date:  2021-10-08       Impact factor: 54.433

6.  Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study.

Authors:  Laila Sara Arroyo Mühr; Carina Eklund; Camilla Lagheden; Ola Forslund; Karin Dahlin Robertsson; Joakim Dillner
Journal:  J Clin Virol       Date:  2022-07-05       Impact factor: 14.481

7.  Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures.

Authors:  Laila Sara Arroyo Mühr; Daniel Guerendiain; Kate Cuschieri; Karin Sundström
Journal:  Viruses       Date:  2021-07-08       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.